Prism Health North Texas is seeking participants for clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222. Seeking 250 participants in the Dallas Fort Worth area out of the 30,000 required across the study, the PHNTX Research Department has been hard at work preparing their systems for enrollment.
For the AZD1222 vaccine study, PHNTX is seeking participants 18 years and older especially in groups that are more likely to be exposed to COVID-19 including people with underlying medical conditions, with greater risk of exposure at their jobs, who live or work in elder-care facilities, jails, or prisons, who are over the age of 65, or are in racial and ethnic groups that have been impacted in greater numbers by the epidemic such as African Americans, Latinx, American Indians, and Alaskan Natives. Those who participate will be compensated for their time and receive a stipend for each visit they complete.
Visits will be held at the Oak Cliff Health Center at 219 Sunset Avenue, Suite 116 and in a new satellite office in East Dallas at 4004 Worth Street.
“We were uniquely positioned to successfully conduct COVID-19 vaccine studies due to the robust research infrastructure we have established over the last 13 years as a clinical research site within the NIH’s HIV research network,” said Dr. Roger Bedimo, Director of NIH-Sponsored Clinical Trials for Prism Health North Texas.
PHNTX is part of the NIH-supported COVID-19 Prevention Network (CoVPN). The CoVPN is composed of existing NIAID-supported clinical research networks with infectious disease expertise and is designed for rapid and thorough evaluation of vaccine candidates and monoclonal antibodies for the prevention of COVID-19.
“Our clinical teams are excited to get started on this important COVID-19 vaccine study, and we already have people signed up, ready to participate,” says Dr. John Carlo, CEO of Prism Health North Texas and member of the Texas Medical Association Taskforce. “Our extensive experience in conducting clinical research studies has enabled us to quickly get the trail up and running, and we are hopeful that our contribution to this international effort quickly finds a safe and effective COVID-19 vaccine.”
Individuals interested in participating may visit phntx.org/services/clinical-research and complete the contact form or email the Research Department directly at email@example.com. They will then be contacted by phone to discuss study participation and eligibility criteria.
AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attach the SARS-CoV-2 virus if it later infects the body.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.